Walsh M. Matthew's Insider Trades & SAST Disclosures
Walsh M. Matthew's most recent trade in Organon & Co. was a trade of 30,414 Common Stock done . Disclosure was reported to the exchange on Feb. 20, 2025.
Add Superstar Alert
Note
This is a custom search result for pattern Walsh M. Matthew.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 30,414 | 122,388 | - | 0 | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.92 per share. | 20 Feb 2025 | 10,662 | 111,726 | - | 14.9 | 159,077 | Common Stock |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 5,570 | 117,296 | - | 0 | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.29 per share. | 20 Feb 2025 | 1,908 | 115,388 | - | 15.3 | 29,173 | Common Stock |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 7,189 | 95,515 | - | 0 | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.35 per share. | 03 Sep 2024 | 3,541 | 91,974 | - | 20.3 | 72,059 | Common Stock |
|
Certara Inc
|
Matthew M. Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 11,928 | 11,928 | - | - | Restricted Stock Units | |
|
Certara Inc
|
Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 185,631 | - | 0 | Common Stock | |
|
Certara Inc
|
Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 0 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 8,310 | 92,419 | - | 0 | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2024 | 8,310 | 0 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.61 per share. | 04 May 2024 | 4,093 | 88,326 | - | 19.6 | 80,264 | Common Stock |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 12,046 | 24,093 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 12,046 | 90,042 | - | 0 | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 7,753 | 81,815 | - | 0 | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 7,753 | 7,754 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.80 per share. | 31 Mar 2024 | 5,933 | 84,109 | - | 18.8 | 111,540 | Common Stock |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.80 per share. | 31 Mar 2024 | 3,819 | 77,996 | - | 18.8 | 71,797 | Common Stock |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 185,185 | 185,185 | - | - | Stock Option (right to buy) | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2024 | 45,212 | 45,212 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Walsh M. Matthew | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,044 | 0 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
M. Walsh Matthew | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,044 | 85,455 | - | - | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.04 per share. | 28 Feb 2024 | 11,393 | 74,062 | - | 18.0 | 205,530 | Common Stock |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 22,347 | 63,417 | - | - | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 22,347 | 0 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 05 Aug 2023 | 11,006 | 52,411 | - | 21.5 | 236,959 | Common Stock |
|
Certara Inc
|
Matthew M. Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 8,663 | 8,663 | - | - | Restricted Stock Units | |
|
Certara Inc
|
Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 9,067 | 0 | - | - | Restricted Stock Units | |
|
Certara Inc
|
Matthew M. Walsh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 9,067 | 176,968 | - | 0 | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 8,310 | 8,310 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 8,310 | 45,113 | - | - | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.24 per share. | 04 May 2023 | 4,043 | 41,070 | - | 24.2 | 98,002 | Common Stock |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 129,770 | 129,770 | - | - | Stock Option (right to buy) | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 36,139 | 36,139 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 7,753 | 39,459 | - | 0 | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 7,753 | 15,507 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.09 per share. | 31 Mar 2023 | 2,656 | 36,803 | - | 23.1 | 61,327 | Common Stock |
|
Certara Inc
|
Matthew M. Walsh | Director | Sale of securities on an exchange or to another person at price $ 14.74 per share. | 14 Nov 2022 | 12,059 | 167,901 | - | 14.7 | 177,750 | Common Stock |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 22,343 | 42,496 | - | - | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 22,343 | 22,343 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.41 per share. | 05 Aug 2022 | 10,790 | 31,706 | - | 32.4 | 349,704 | Common Stock |
|
Certara Inc
|
Matthew M. Walsh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 9,067 | 9,067 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 8,310 | 8,310 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 8,310 | 23,000 | - | - | Common Stock | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.44 per share. | 04 May 2022 | 2,847 | 20,153 | - | 32.4 | 92,357 | Common Stock |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 71,649 | 71,649 | - | - | Stock Option (right to buy) | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 23,260 | 23,260 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 44,642 | 44,642 | - | - | Stock Option (Right to Buy) | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 22,343 | 44,690 | - | - | Restricted Stock Units | |
|
Organon & Co.
|
Matthew M. Walsh | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.63 per share. | 05 Aug 2021 | 22,343 | 22,343 | - | 28.6 | 639,680 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges